Why Eli Lilly's Successful Alzheimer's Disease Study Was So Disappointing

25
4
Favorite

Why Eli Lilly's Successful Alzheimer's Disease Study Was So Disappointing

Motley Fool2021-03-15

Eli Lilly's latest Alzheimer's disease candidate is a terrific success and a disappointing flop at the same time.Attention forEli Lilly(NYSE:LLY)has been blowing up since the company announced success...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment（4）

BellcurveGod
·2021-03-16
Heng nve enter
Reply
3
Report
zeeling
·2021-03-16
This is cool
Reply
1
Report
Fold Replies
- BellcurveGod:
  .
  2021-03-16
  Reply
  Report
Baper
·2021-03-15
Hiello
Reply
4
Report
Fold Replies
- JiaJun87:
  Hmm
  2021-03-15
  Reply
  Report
- alicialjw:
  Hi
  2021-03-15
  Reply
  Report
_J_R_
·2021-03-15
Hmmm
Reply
3
Report
Fold Replies
- alicialjw:
  Ye
  2021-03-15
  Reply
  Report

Most Discussed

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/1110886827?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2021-03-15 22:47","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1110886827","market":"us","top_or_hot":-1,"title":"Why Eli Lilly's Successful Alzheimer's Disease Study Was So Disappointing","media":"Motley Fool","content":"<div>\n<p>Eli Lilly's latest Alzheimer's disease candidate is a terrific success and a disappointing flop at the same time.Attention forEli Lilly(NYSE:LLY)has been blowing up since the company announced success...</p>\n\n<a href=\"https://www.fool.com/investing/2021/03/15/eli-lilly-reports-underwhelming-alzheimers-disease/\">Source Link</a>\n\n</div>\n","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Eli Lilly's Successful Alzheimer's Disease Study Was So Disappointing</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Eli Lilly's Successful Alzheimer's Disease Study Was So Disappointing\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-03-15 22:47 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/03/15/eli-lilly-reports-underwhelming-alzheimers-disease/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Eli Lilly's latest Alzheimer's disease candidate is a terrific success and a disappointing flop at the same time.Attention forEli Lilly(NYSE:LLY)has been blowing up since the company announced success...</p>\n\n<a href=\"https://www.fool.com/investing/2021/03/15/eli-lilly-reports-underwhelming-alzheimers-disease/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LLY","symbol_name":"礼来","start_time":0,"source_url":"https://www.fool.com/investing/2021/03/15/eli-lilly-reports-underwhelming-alzheimers-disease/","article_id":"1110886827","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1110886827","pubTimestamp":1615819641,"sourceInfo":null,"weMediaInfo":null,"summary":"Eli Lilly's latest Alzheimer's disease candidate is a terrific success and a disappointing flop at t","collect":0,"end_time":0,"defaultTopTitle":"fool.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"LLY":"礼来"},"translate_title":"为什么礼来成功的阿尔茨海默病研究如此令人失望","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LLY":0.9},"content_text":"Eli Lilly's latest Alzheimer's disease candidate is a terrific success and a disappointing flop at the same time.Attention forEli Lilly(NYSE:LLY)has been blowing up since the company announced success for its experimental new Alzheimer's disease drug. Unfortunately, the results strongly suggest that Eli Lilly andBiogen(NASDAQ:BIIB)have a lot more work to do.How can a clinical trial that succeeded also foreshadow a slow-motion trainwreck? Strap in for some nuance.Technically a successThe phase 2 Trailblazer trial rounded up hundreds of people with early stage Alzheimer's disease and treated them with either a placebo or donanemab to see if the experimental antibody could prevent their disease from getting worse.Earlier this year, Eli Lilly sparked a lot of hope for donanemab by telling everybody the Trailblazer trial met its main goal. That goal was a significantly improved score on a relatively new test to measure patients' cognitive and functional abilities. After treating 257 patients for 76 weeks, test scores for those given a placebo deteriorated 46% further than test scores for patients randomized to receive donanemab.Donanemab works in the brain to reduce the formation of dangerous plaques made of amyloid protein fragments. After 76 weeks, comparing brain scans also showed huge amyloid plaque reductions for those given donanemab compared to those given a placebo.Why donanemab disappointedDonanemab significantly slowed patients' rate of decline on the integrated Alzheimer's disease rating scale. The iADRS combines a commonly used cognition test with a test that measures AD patients' ability to function as adults.The FDA has never reviewed an application for a potential new Alzheimer's disease drug based on a successful iADRS score. That could be a big problem for Eli Lilly because the Trailblazer study assaulted trial participants with a battery of different tests and the iADRS was the only measurement in which donanemab provided a statistically significant benefit.Moreover, the benefit wasn't any better than Eli Lilly reported for solanezumab years ago. This twice-failed amyloid remover from Eli Lilly couldn't meet its primary endpoint in phase 3 trials, but it did lead to significantly improved iADRS scores.This isn't workingDonanemab is similar to solanezumab, except it appears far more effective at removing amyloid deposits and preventing their formation. This is why Eli Lilly was eager to make the iADRS test aprimary endpointfor donanemab trials, and extra careful to select trial volunteers that already had lots of amyloid deposits to remove.If the donanemab program went according to plan, more amyloid to remove, plus a better drug to remove it should have led to an iADRS score benefit that rang clear as a bell. What happened was far less satisfying.Patients began the Trailblazer trial with average iADRS scores of 106 points out of a potential 141 points. After 76 weeks, those given a placebo averaged just 3.2 points lower than those given donanemab.Unfortunately, those given donanemab didn't improve or even hold steady. In fact, their average scores fell by 6.9 points.What's nextThe Trailblazer trial is another clear sign that removing amyloid deposits isn't a surefire way to stop the progression of AD, but it appears to work well for some. Decades from now we'll probably think of AD as a collection of different diseases, just one or two of which respond to drugs like donanemab on their own. In the meantime, U.S. regulators have a controversial decision to make that could help us understand the connection between amyloid knockdowns and the disease.The FDA iseager to approvean amyloid-clearing AD drug from Biogen called aducanumab even though independent experts unanimously agree that pivotal trial results didn't show evidence of a benefit. If approved, widespread adoption of Biogen's drug could elucidate just which AD patients respond well to amyloid knockdowns and which don't. The line between Biogen's and Eli Lilly's attempts to treat AD isn't a straight one, but donanemab's future depends on the FDA's willingness to bend the rules for aducanumab.Alzheimer's disease affects one out of nine adults over the age of 65 and a dearth of available treatments means the first one will become one of the top-selling drugs of its time. With such an enormous pot of gold at the end of this rainbow, we can't fault Eli Lilly for making further attempts with donanemab. Unfortunately, its chances of success don't look very good.Lilly dipped more than 8% in Monday trading.","kind":"news","is_publish_news":false,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":325004377,"gmtCreate":1615848198899,"gmtModify":1704787329870,"author":{"id":"3566941403316155","authorId":"3566941403316155","name":"BellcurveGod","avatar":"https://static.tigerbbs.com/ecbcd3f60b238d816cc0bffd5fd9df5d","vip":1,"crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"3566941403316155","idStr":"3566941403316155"},"htmlText":"Heng nve enter","listText":"Heng nve enter","text":"Heng nve enter","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/325004377","repostId":1110886827,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":322769562,"gmtCreate":1615829393056,"gmtModify":1704787260562,"author":{"id":"3578196134540225","authorId":"3578196134540225","name":"zeeling","avatar":"https://static.tigerbbs.com/901d745faf2cd5225a6dbed44ad6236a","vip":1,"crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"3578196134540225","idStr":"3578196134540225"},"htmlText":"This is cool","listText":"This is cool","text":"This is cool","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/322769562","repostId":1110886827,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":3802494,"gmtCreate":1615848215614,"gmtModify":1680780487262,"authorId":3566941403316155,"author":{"id":3566941403316155,"idStr":"3566941403316155","authorId":3566941403316155,"name":"BellcurveGod","avatar":"https://static.tigerbbs.com/ecbcd3f60b238d816cc0bffd5fd9df5d","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":322769562,"type":1,"supId":0,"prevId":0,"content":".","text":".","html":"."}],"langContent":"EN"},{"id":322487202,"gmtCreate":1615820904706,"gmtModify":1704787125354,"author":{"id":"3574683709420484","authorId":"3574683709420484","name":"Baper","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"3574683709420484","idStr":"3574683709420484"},"htmlText":"Hiello","listText":"Hiello","text":"Hiello","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/322487202","repostId":1110886827,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":3801031,"gmtCreate":1615821390796,"gmtModify":1680780468358,"authorId":3573875235773606,"author":{"id":3573875235773606,"idStr":"3573875235773606","authorId":3573875235773606,"name":"JiaJun87","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"currentWearingBadge":{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.10.13","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1001},"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":322487202,"type":1,"supId":0,"prevId":0,"content":"Hmm","text":"Hmm","html":"Hmm"},{"id":3800980,"gmtCreate":1615821097559,"gmtModify":1680780467524,"authorId":3574747299650124,"author":{"id":3574747299650124,"idStr":"3574747299650124","authorId":3574747299650124,"name":"alicialjw","avatar":"https://static.tigerbbs.com/75446939ff21a7803eb236a4c6a5395c","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":322487202,"type":1,"supId":0,"prevId":0,"content":"<u>Hi</u>","text":"<u>Hi</u>","html":"<u>Hi</u>"}],"langContent":"EN"},{"id":322437697,"gmtCreate":1615819974319,"gmtModify":1704787097160,"author":{"id":"3578740811020073","authorId":"3578740811020073","name":"_J_R_","avatar":"https://static.tigerbbs.com/ea3e25891715133cf383f8a5bbd5435a","vip":1,"hat":"https://static.tigerbbs.com/b0a2963eb37c60c5d6d4a8dbcd266952","crmLevel":4,"crmLevelSwitch":1,"authorIdStr":"3578740811020073","idStr":"3578740811020073"},"htmlText":"Hmmm","listText":"Hmmm","text":"Hmmm","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/322437697","repostId":1110886827,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":3800976,"gmtCreate":1615821089711,"gmtModify":1680780464510,"authorId":3574747299650124,"author":{"id":3574747299650124,"idStr":"3574747299650124","authorId":3574747299650124,"name":"alicialjw","avatar":"https://static.tigerbbs.com/75446939ff21a7803eb236a4c6a5395c","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":322437697,"type":1,"supId":0,"prevId":0,"content":"<u>Ye</u>","text":"<u>Ye</u>","html":"<u>Ye</u>"}],"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":25,"commentSize":4,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}